Epidemiology and risk factors of community onset infections caused by extended-spectrum β-lactamase-producing Escherichia coli strains

Journal of Clinical Microbiology

Volumn 50, Issue 2, 2012, Pages 312-317

  Kang, Cheol In ^a   Wi, Yu Mi ^a   Lee, Mi Young ^b   Ko, Kwan Soo ^a,b   Chung, Doo Ryeon ^a   Peck, Kyong Ran ^a   Lee, Nam Yong ^a   Songa, Jae Hoon ^a,b  

^a Sungkyunkwan University School of Medicine   (South Korea)

^b Asia Pacific Foundation for Infection Diseases (APFID)   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; BETA LACTAMASE CTX M; BETA LACTAMASE CTX M 14; BETA LACTAMASE CTX M 15; CEFEPIME; CEFOTAXIME; CEFTAZIDIME; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; COTRIMOXAZOLE; ERTAPENEM; GENTAMICIN; IMIPENEM; LEVOFLOXACIN; MEROPENEM; PENICILLIN DERIVATIVE; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TOBRAMYCIN; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM CULTURE; BACTERIUM ISOLATE; BACTERIUM ISOLATION; CASE CONTROL STUDY; COMMUNICABLE DISEASE; CONTROLLED STUDY; DISEASE SEVERITY; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTION; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING ESCHERICHIA COLI; FEMALE; HOSPITAL INFECTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR PHYLOGENY; NONHUMAN; PRIORITY JOURNAL; RISK FACTOR; URINARY TRACT INFECTION;

AGED; AGED, 80 AND OVER; BETA-LACTAMASES; CASE-CONTROL STUDIES; COMMUNITY-ACQUIRED INFECTIONS; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; RISK FACTORS;

ESCHERICHIA COLI;

EID: 84862908371     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.06002-11     Document Type: Article

References (24)

1. Arpin C, et al. 2003. Extended-spectrum beta-lactamase-producing Enterobacteriaceae in community and private health care centers. Antimicrob. Agents Chemother. 47:3506-3514. (Pubitemid 37345711)
2. Azap OK, et al. 2010. Risk factors for extended-spectrum beta-lactamase positivity in uropathogenic Escherichia coli isolated from community-acquired urinary tract infections. Clin. Microbiol. Infect. 16:147-151.
3. Ben-Ami R, et al. 2009. A multinational survey of risk factors for infection with extended-spectrum beta-lactamase-producing Enterobacteriaceae in nonhospitalized patients. Clin. Infect. Dis. 49:682-690.
4. Calbo E, et al. 2006. Risk factors for community-onset urinary tract infections due to Escherichia coli harbouring extended-spectrum beta-lactamases. J. Antimicrob. Chemother. 57:780-783.
5. Cheong HS, et al. 2010. Prevalence of extended-spectrum beta-lactamase among Enterobacteriaceae blood isolates with inducible AmpC betalactamase. Infect. Chemother. 42:280-284.
6. Friedman ND, et al. 2002. Health care-associated bloodstream infections in adults: a reason to change the accepted definition of communityacquired infections. Ann. Intern. Med. 137:791-797. (Pubitemid 35334450)
7. Garner JS, Jarvis WR, Emori TG, Horan TC, Hughes JM. 1988. CDC definitions for nosocomial infections, 1988. Am. J. Infect. Control 16: 128-140.
8. Harris AD, Karchmer TB, Carmeli Y, Samore MH. 2001. Methodological principles of case-control studies that analyzed risk factors for antibiotic resistance: a systematic review. Clin. Infect. Dis. 32:1055-1061. (Pubitemid 32299641)
9. Harris AD, et al. 2002. Control-group selection importance in studies of antimicrobial resistance: examples applied to Pseudomonas aeruginosa, enterococci, and Escherichia coli. Clin. Infect. Dis. 34:1558-1563. (Pubitemid 34615439)
10. Hyle EP, et al. 2005. Risk factors for increasing multidrug resistance among extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella species. Clin. Infect. Dis. 40:1317-1324. (Pubitemid 40570242)
11. Kang CI, et al. 2008. Clinical features and outcome of community-onset bloodstream infections caused by extended-spectrum beta-lactamase-producing Escherichia coli. Eur. J. Clin. Microbiol. Infect. Dis. 27:85-88.
12. Kang CI, et al. 2010. Risk factors and treatment outcomes of community- onset bacteraemia caused by extended-spectrum beta-lactamase-producing Escherichia coli. Int. J. Antimicrob. Agents 36:284-287.
13. Kim J, Lim YM, Jeong YS, Seol SY. 2005. Occurrence of CTX-M-3, CTX-M-15, CTX-M-14, and CTX-M-9 extended-spectrum betalactamases in Enterobacteriaceae clinical isolates in Korea. Antimicrob. Agents Chemother. 49:1572-1575. (Pubitemid 40463392)
14. Kim J, et al. 2005. CTX-M and SHV-12 beta-lactamases are the most common extended-spectrum enzymes in clinical isolates of Escherichia coli and Klebsiella pneumoniae collected from 3 university hospitals within Korea. FEMS Microbiol. Lett. 245:93-98. (Pubitemid 40410682)
15. Ko KS, et al. 2007. In vitro activity of fosfomycin against ciprofloxacin-resistant or extended-spectrum beta-lactamase-producing Escherichia coli isolated from urine and blood. Diagn. Microbiol. Infect. Dis. 58:111-115.
16. Meier S, Weber R, Zbinden R, Ruef C, Hasse B. 2011. Extended-spectrum beta-lactamase-producing Gram-negative pathogens in community-acquired urinary tract infections: an increasing challenge for antimicrobial therapy. Infection 39:333-340.
17. Park SH, et al. 2011. Emergence of extended-spectrum beta-lactamase- producing Escherichia coli as a cause of community-onset bacteremia in South Korea: risk factors and clinical outcomes. Microb. Drug Resist. 17:537-544.
18. Paterson DL, Bonomo RA. 2005. Extended-spectrum beta-lactamases: a clinical update. Clin. Microbiol. Rev. 18:657-686.
19. Perl TM, Dvorak L, Hwang T, Wenzel RP. 1995. Long-term survival and function after suspected gram-negative sepsis. JAMA 274:338-345.
20. Pitout JD. 2010. The latest threat in the war on antimicrobial resistance. Lancet Infect. Dis. 10:578-579.
21. Pitout JD, Laupland KB. 2008. Extended-spectrum beta-lactamase-producing Enterobacteriaceae: an emerging public-health concern. Lancet Infect. Dis. 8:159-166. (Pubitemid 351249250)
22. Rodriguez-Bano J, et al. 2008. Community infections caused by extended-spectrum beta-lactamase-producing Escherichia coli. Arch. Intern. Med. 168:1897-1902.
23. Rodriguez-Bano J, et al. 2010. Community-onset bacteremia due to extended-spectrum beta-lactamase-producing Escherichia coli: risk factors and prognosis. Clin. Infect. Dis. 50:40-48.
24. Valverde A, et al. 2004. Dramatic increase in prevalence of fecal carriage of extended-spectrum beta-lactamase-producing Enterobacteriaceae during nonoutbreak situations in Spain. J. Clin. Microbiol. 42:4769-4775. (Pubitemid 39362401)